Cytokinetics Inc vs JetBlue Airways Corporation — how do they compare? Cytokinetics Inc trades at $76.66 (market cap $10.78B), while JetBlue Airways Corporation trades at $5.81 (market cap $2.13B). The key difference: Cytokinetics Inc is far larger — about 5.1× JetBlue Airways Corporation's market cap. Which is the better fit depends on your goals.
| CYTK | JBLU | |
|---|---|---|
Market Cap | $10.78B | $2.13B |
Sector | Technology | Industrials |
52-Week High | $87.26 | $6.46 |
52-Week Low | $34.31 | $4.03 |
Enterprise Value | $10.88B | $9.49B |
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
No Aura AI signal available yet.
Trailing returns across standard periods
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →